Differentiated Thyroid Cancer
58
13
18
17
Key Insights
Highlights
Success Rate
77% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
8.6%
5 terminated out of 58 trials
77.3%
-9.2% vs benchmark
14%
8 trials in Phase 3/4
47%
8 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (58)
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
Pembrolizumab in High-risk Thyroid Cancer
Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Empirical Radioactive Iodine Therapy in DTC
Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers
F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy
Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
Iodine Uptake After a Low Iodine Diet
IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
No Prognostic or Molecular Disparity Between Synchronous and Metachronous Metastases in Differentiated Thyroid Cancer: Insight From Middle Eastern Cohort